LHHC Medical Technology, a China AI company, announced a global cooperation with Vancouver’s Enlighta to market LHHC’s early cancer detection test. The “No Cancer” technology combines LHHC’s AI data models and algorithm with conventional blood test data, specifically for individuals of Chinese and Asian ancestry. It assesses an individual’s risk of developing any one of thirteen early-stage cancers, allowing early prevention and intervention. The test, which aims to identify any immunological abnormalities, has an 85% accuracy, said LHHC. LHHC was formed by scientists from well-known China universities. Source: China Biotoday
